Levi & Korsinsky Notifies Shareholders of Novo Nordisk A/S(NVO) of a Class Action Lawsuit and an Upcoming Deadline

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S due to alleged securities fraud affecting investors between November 2, 2022, and December 19, 2024 [1] Group 1: Lawsuit Details - The lawsuit was initiated following Novo's announcement on December 20, 2024, regarding disappointing results from the "REDEFINE 1" trial, which investigated the efficacy and safety of subcutaneous CagriSema [2] - The trial results indicated that patients treated with CagriSema experienced a weight loss of 22.7% after 68 weeks, falling short of the company's target of at least 25% [2] - Following the announcement, Novo's stock price dropped by $18.44 per share, closing at$85.00 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 25, 2025, to request appointment as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]